Holland Capital invests in Lynxcare

Holland Capital invests in LynxCare to accelerate the expansion of its federated hospital network across Europe 

Holland Capital joins with the unanimous support of existing investors. Sue Beecroft has been appointed Chair of the Board. 

LynxCare, the Belgian clinical informatics company co-founded by Dr. Dries Hens, which transforms hospital data into real-world evidence for research, announces a capital increase welcoming Holland Capital as a new investor. Holland Capital, a Dutch investment firm with a strong track record in health tech, joins existing investors Elaia, HERAN Partners, b2venture and Matterwave Ventures, MTIP, and Vassoyan Conseil, who continue to back the company's growth.

Together with the appointment of Sue Beecroft as Chair of the Board, the investment marks the next phase for LynxCare: activating and scaling its European hospital network for multi-country research. 

Access to essential Real-World Data 

Traditional clinical trials test treatments in a strictly selected group of patients. Hospital records on the other hand show how those treatments perform in routine care, across a much broader and more diverse patient population in the real world. 

Yet much of that valuable clinical information - whether a tumour has progressed, how a patient responded to treatment, which side effects occurred - is written as free text in physician notes, pathology reports and discharge letters, not recorded in structured fields. LynxCare unlocks this information with its own small clinical language models. Unlike general-purpose AI, they are trained specifically on clinical text and extract detailed clinical information in an accurate and structured way. Because the models are compact, they can run efficiently on standard hospital infrastructure without sensitive clinical data leaving the hospital.